Effect of increasing doses of colchicine on the treatment of 333 COVID‐19 inpatients

Abstract

BackgroundPrevious research done in Bulgaria demonstrated a fivefold reduction in mortality from COVID‐19 with increased doses of colchicine from two hospitals in the country. We report here a further 333 cases of COVID‐19 inpatients, treated with different doses of colchicine and its effect on mortality.Materials and MethodsA case‐control comparison from two additional hospitals was conducted between increased doses of colchicine and added bromhexine to standard of care (SOC) versus current SOC. Risk and odds ratio, as well as subgroup analysis, was conducted with newly reported data, alongside aggregate data from all hospital centers to determine the extent of mortality reduction in COVID‐19 inpatients.ResultsThere was a clear reduction in the mortality of inpatients with increasing doses of colchicine—between twofold and sevenfold. Colchicine loading doses of 4 mg are more effective than those with 2 mg. Despite these doses being higher than the so‐called “standard doses,” colchicine inpatients experienced lower mortality than SOC patients (5.7% vs. 19.53%). This mortality benefit was evident in different age subgroups, with a 4‐mg loading dose of colchicine proving slightly superior to a 2‐mg loading dose. Colchicine led to an overall relative risk reduction of 70.7%, with SOC patients having 3.91 higher odds of death. The safety of the doses was not different than the reported in the summary of product characteristics.ConclusionInpatients in Bulgaria with added colchicine and bromhexine to SOC achieved better clinical and mortality outcomes than those on SOC alone. These results question the World Health Organization—recommended strategy to inhibit viral replication. We posit that our treatment strategy to inhibit the Severe acute respiratory syndrome coronavirus 2 entry into the cell with inhaled bromhexine and the hyperactivated NLRP3 inflammasome with higher doses of colchicine, prevents the development of cytokine storm. The timing of the initiation of treatment seems critical.

Successful Treatment With High-Dose Colchicine of a 101-Year-Old Patient Diagnosed With COVID-19 After an Emergency Cholecystectomy

“…Our case highlights the potentially life-saving effect of timely initiated therapy with appropriate high-dose colchicine in severely deconditioned surgical patients with multiple comorbidities and advanced age. In our recent study of 785 inpatients, we have shown that higher doses of colchicine are dose-dependently associated with a two-to seven-fold decrease in mortality [5,7].…”

“…Our team has been struggling for years to prove that high doses of colchicine are life-saving in severe COVID-19 [4][5][6][7][8][9][10]. Our therapeutic strategy is based on inhibiting SARS-CoV-2 entry into the cell (by bromhexine hydrochloride) and inhibiting the NLRP3 inflammasome (by colchicine), two readily available, cheap, and well-known medications.…”

“…COVID-19 death rates were higher for men than women of all races among adults aged 65 and over [2]. We have previously demonstrated that using high-dose colchicine for severely ill COVID-19 inpatients leads to a decreased mortality rate between two and sevenfold, depending on the dosage [4][5][6][7]. The explanation for the effect of high doses of colchicine is that only in this way can the NOD-, LRR-and pyrin domain-containing protein 3 (NLRP3) inflammasome, whose hyperactivation is responsible for the cytokine storm and subsequent multiorgan damage and death, be inhibited [8].…”